Next/second-line therapies
| . | R-B (n = 21) . | R-CHOP/R-DHAP (n = 75) . |
|---|---|---|
| Individual treatments | ||
| Cytarabine based | ||
| R-high-dose cytarabine | 0 | 11 (15) |
| R-DHAP | 1 (5) | 9 (12) |
| DEXA-BEAM | 0 | 5 (7) |
| R-Hyper-CVAD | 0 | 2 (3) |
| R-B | 0 | 12 (16) |
| R-FC | 0 | 8 (11)* |
| BTK inhibitor | 11 (52) | 2 (3) |
| R-CHOP | 7 (33) | 1 (1) |
| Bortezomib-based | 0 | 5 (7) |
| Radiation alone | 0 | 4 (5) |
| Temsirolimus | 0 | 3 (4) |
| Other | 2 (10)† | 10 (13)‡ |
| Unknown | 0 | 3 (4) |
| Stem cell transplantation | ||
| Allogeneic | 3 (14) | 11 (15) |
| Autologous | 0 | 5 (7)§ |
| . | R-B (n = 21) . | R-CHOP/R-DHAP (n = 75) . |
|---|---|---|
| Individual treatments | ||
| Cytarabine based | ||
| R-high-dose cytarabine | 0 | 11 (15) |
| R-DHAP | 1 (5) | 9 (12) |
| DEXA-BEAM | 0 | 5 (7) |
| R-Hyper-CVAD | 0 | 2 (3) |
| R-B | 0 | 12 (16) |
| R-FC | 0 | 8 (11)* |
| BTK inhibitor | 11 (52) | 2 (3) |
| R-CHOP | 7 (33) | 1 (1) |
| Bortezomib-based | 0 | 5 (7) |
| Radiation alone | 0 | 4 (5) |
| Temsirolimus | 0 | 3 (4) |
| Other | 2 (10)† | 10 (13)‡ |
| Unknown | 0 | 3 (4) |
| Stem cell transplantation | ||
| Allogeneic | 3 (14) | 11 (15) |
| Autologous | 0 | 5 (7)§ |
DEXA-BEAM, dexamethasone, carmustine, etoposide, cytarabine, melphalan.
Includes 2 patients who also received mitoxantrone.
One R-GDP and 1 HDMTX.
Other: 3 R-ICE, 3 directly to stem cell transplant, 1 intrathecal chemotherapy, 1 rituximab monotherapy, and 1 MCL-002 trial.
None had previously received ASCT as consolidation after R-CHOP/R-DHAP.